236 related articles for article (PubMed ID: 7673253)
1. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
[TBL] [Abstract][Full Text] [Related]
2. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch C; Weiss FU; Niederfellner G; Jallal B; Issing W; Ullrich A
EMBO J; 1995 Sep; 14(17):4267-75. PubMed ID: 7556068
[TBL] [Abstract][Full Text] [Related]
3. NDF/heregulin stimulates the phosphorylation of Her3/erbB3.
Kita YA; Barff J; Luo Y; Wen D; Brankow D; Hu S; Liu N; Prigent SA; Gullick WJ; Nicolson M
FEBS Lett; 1994 Jul; 349(1):139-43. PubMed ID: 8045292
[TBL] [Abstract][Full Text] [Related]
4. Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3.
Vartanian T; Goodearl A; Viehöver A; Fischbach G
J Cell Biol; 1997 Apr; 137(1):211-20. PubMed ID: 9105049
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of Paget's disease: epidermal heregulin-alpha, motility factor, and the HER receptor family.
Schelfhout VR; Coene ED; Delaey B; Thys S; Page DL; De Potter CR
J Natl Cancer Inst; 2000 Apr; 92(8):622-8. PubMed ID: 10772679
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski MX; Schaefer G; Akita RW; Lofgren JA; Fitzpatrick VD; Nuijens A; Fendly BM; Cerione RA; Vandlen RL; Carraway KL
J Biol Chem; 1994 May; 269(20):14661-5. PubMed ID: 7514177
[TBL] [Abstract][Full Text] [Related]
7. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
8. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.
Plowman GD; Green JM; Culouscou JM; Carlton GW; Rothwell VM; Buckley S
Nature; 1993 Dec; 366(6454):473-5. PubMed ID: 7902537
[TBL] [Abstract][Full Text] [Related]
9. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4.
Chen X; Levkowitz G; Tzahar E; Karunagaran D; Lavi S; Ben-Baruch N; Leitner O; Ratzkin BJ; Bacus SS; Yarden Y
J Biol Chem; 1996 Mar; 271(13):7620-9. PubMed ID: 8631797
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor.
Culouscou JM; Plowman GD; Carlton GW; Green JM; Shoyab M
J Biol Chem; 1993 Sep; 268(25):18407-10. PubMed ID: 7689552
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
Int J Cancer; 1995 Mar; 60(5):730-9. PubMed ID: 7860149
[TBL] [Abstract][Full Text] [Related]
12. HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein.
Siegall CB; Bacus SS; Cohen BD; Plowman GD; Mixan B; Chace D; Chin DM; Goetze A; Green JM; Hellström I
J Biol Chem; 1995 Mar; 270(13):7625-30. PubMed ID: 7535774
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
14. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma.
Gilbertson RJ; Perry RH; Kelly PJ; Pearson AD; Lunec J
Cancer Res; 1997 Aug; 57(15):3272-80. PubMed ID: 9242460
[TBL] [Abstract][Full Text] [Related]
16. Heregulins and the ErbB-2/3/4 receptors in gliomas.
Westphal M; Meima L; Szonyi E; Lofgren J; Meissner H; Hamel W; Nikolics K; Sliwkowski MX
J Neurooncol; 1997 Dec; 35(3):335-46. PubMed ID: 9440030
[TBL] [Abstract][Full Text] [Related]
17. Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3.
Horan T; Wen J; Arakawa T; Liu N; Brankow D; Hu S; Ratzkin B; Philo JS
J Biol Chem; 1995 Oct; 270(41):24604-8. PubMed ID: 7592681
[TBL] [Abstract][Full Text] [Related]
18. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
[TBL] [Abstract][Full Text] [Related]
19. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
20. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
